BCAL Diagnostics (ASX:BDX) has strengthened its board with the appointment of experienced healthcare technology executive Mark McConnell as a Non-Executive Director, effective 1 February 2026.
Mr McConnell brings extensive leadership, strategic and capital markets experience to BCAL, aligning closely with the company’s next phase of growth as it advances the commercialisation of its flagship breast cancer screening technology, BREASTEST plus™, and progresses its broader early cancer detection strategy.
He is best known for leading Magentus through its transformation into a leading global health technology company. Mr McConnell was also a co-founder of The Citadel Group Limited, a former ASX-listed software and services business that laid the foundations for what is now Magentus Group. Across a career spanning nearly three decades, he has held senior executive roles across aviation, technology and investment banking, following almost ten years of service as an officer in the Royal Australian Air Force.
In addition to his commercial background, Mr McConnell has a strong commitment to community and governance, having served on the boards of numerous charitable, not-for-profit and sporting organisations. He currently also serves as a Non-Executive Director of Adveritas Ltd (ASX: AV1).
BCAL Executive Chair Jayne Shaw welcomed the appointment, noting that Mr McConnell’s experience in scaling healthcare technology businesses and navigating complex corporate transformations would be highly valuable as the company moves forward. She said his deep understanding of ASX-listed environments, combined with his expertise in investor engagement and capital raising, would support BCAL as it transitions toward commercial execution.
BCAL Diagnostics is focused on improving early and accurate cancer detection, with its lead product, BREASTEST plus, positioned as a non-invasive, lipid-based blood test designed to be used alongside mammography in women with dense breasts. The company also holds an exclusive licence to distribute pancreatic and ovarian cancer blood tests developed by US-based precision diagnostics company ClearNote Health in Australia.